BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022

Rhea-AI Summary

BioLife Solutions (NASDAQ: BLFS) will release its third quarter 2022 financial results after market close on November 9, 2022. A conference call and live webcast are scheduled for 4:30 PM ET the same day, where management will share financial insights and a business update. Investors can access the conference via the company's Investor Relations page. BioLife Solutions specializes in bioproduction tools and services aimed at cell and gene therapies, positioning itself as a key player in the biopharma sector.

Positive

• Scheduled release of third quarter financial results indicates transparency and ongoing communication with investors.
• BioLife Solutions is a leading supplier in the growing cell and gene therapy market.

Negative

• None.

BOTHELL, Wash., Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2022 financial results will be released after market close on Wednesday, November 9^th. The Company will host a conference call and live webcast at 4:30pm ET (1:30pm PT) that day.  Management will provide an overview of the Company's financial results and a general business update.

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers. The conference ID number is 8988696. A webcast replay will be available approximately two hours after the call and will be archived on https://www.biolifesolutions.com/ for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets. Our tools portfolio includes our proprietary CryoStor^® and HypoThermosol^® biopreservation media for shipping and storage, the ThawSTAR^® family of automated, water-free thawing products, evo^® cold chain management system,  high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools.  For more information, please visit www.biolifesolutions.com, www.scisafe.com, www.stirlingultracold.com, or www.sextonbio.com and follow BioLife on Twitter.

Contact Information:

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com

Investors
LHA Investor Relations
Jody Cain
(310) 691-7100
jcain@lhai.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-to-report-third-quarter-2022-financial-results-and-provide-business-update-on-november-9-2022-301666159.html

SOURCE BioLife Solutions, Inc.

FAQ

When will BioLife Solutions report its third quarter 2022 financial results?

BioLife Solutions will report its third quarter 2022 financial results on November 9, 2022.

What time is the BioLife Solutions conference call on November 9, 2022?

The conference call is scheduled for 4:30 PM ET on November 9, 2022.

Where can I access the BioLife Solutions third quarter earnings webcast?

The webcast can be accessed on the Investor Relations page of the BioLife Solutions website.

What is the significance of BioLife Solutions' position in the biopharma market?

BioLife Solutions is noted for supplying critical bioproduction tools and services for cell and gene therapies, making it a key player in the biopharma industry.